{
    "id": "114cd6ad-9203-4034-b390-3e0901e064a4",
    "indications": {
        "text": "welireg hypoxia-inducible factor inhibitor indicated : von hippel-lindau ( vhl ) disease treatment adult patients von hippel-lindau ( vhl ) disease require therapy associated renal cell carcinoma ( rcc ) , central nervous system ( cns ) hemangioblastomas , pancreatic neuroendocrine tumors ( pnet ) , requiring immediate surgery . ( 1.1 ) advanced renal cell carcinoma ( rcc ) treatment adult patients advanced renal cell carcinoma ( rcc ) clear cell component following programmed death receptor-1 ( pd-1 ) programmed death-ligand 1 ( pd-l1 ) inhibitor vascular endothelial growth factor tyrosine kinase inhibitor ( vegf-tki ) . ( 1.2 ) pheochromocytoma paraganglioma ( ppgl ) treatment adult pediatric patients 12 years older locally advanced , unresectable , metastatic pheochromocytoma paraganglioma ( ppgl ) . ( 1.3 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "renal cell carcinoma (DOID:4450)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4450"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "pheochromocytoma (DOID:0050771)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050771"
            },
            {
                "text": "paraganglioma (DOID:0050773)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050773"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended welireg adult patients 120 mg administered orally daily without food . ( 2.1 ) recommended welireg pediatric patients 12 years older based bodyweight : patients weighing \u2265 40 kg : 120 mg orally daily patients weighing < 40 kg : 80 mg orally daily",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "BELZUTIFAN",
            "code": "7K28NB895L",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15463"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MPA.S)",
            "code": "6N003M473W",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30089"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "organization": "Merck Sharp & Dohme LLC",
    "name": "WELIREG",
    "effectiveTime": "20250514",
    "indications_original": "WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).   ( 1.3 )",
    "contraindications_original": "The recommended dosage of WELIREG in adult patients is 120 mg administered orally once daily with or without food. ( 2.1 ) The recommended dosage of WELIREG in pediatric patients 12 years and older is based on bodyweight: Patients weighing \u2265 40 kg: 120 mg orally once daily Patients weighing < 40 kg: 80 mg orally once daily",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "WELIREG",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15463"
        }
    ]
}